Capillary Hyperpermeability Syndrome

Capillary hyperpermeability syndrome means the tiny blood vessels (capillaries) suddenly become “too leaky.” When they leak, protein-rich plasma leaves the bloodstream and moves into surrounding tissues and muscle compartments. This causes low blood pressure, thickened blood (because water leaves the vessels), and low blood albumin. Doctors often call the dramatic, recurrent form systemic capillary leak syndrome (SCLS) or Clarkson disease. A classic triad helps doctors recognize attacks: hypotension, hemoconcentration, and hypoalbuminemia in the absence of other causes. American College of Physicians Journals+1

Capillary hyperpermeability syndrome is a rare disease where the walls of very small blood vessels become leaky all at once. Fluid and proteins spill out of the bloodstream into muscles and tissues. Because the bloodstream suddenly loses volume, blood pressure drops and organs do not get enough blood. The blood that remains becomes thicker (high hematocrit), and albumin falls. People may have severe swelling, kidney injury, muscle breakdown, and sometimes compartment syndrome that needs emergency surgery to save limbs. Between attacks, many people feel normal. Monthly IVIG helps prevent future attacks in many patients. PMC+3Orpha+3JACI Online+3

Many people with idiopathic (primary) SCLS report a flu-like illness before an attack. Episodes can recur over months or years and may vary in severity. PMC+1

A key part of the leak involves damage to the endothelial glycocalyx, a gel-like protective layer lining the inside of capillaries that normally controls permeability and prevents inflammation and clotting. When this layer is injured by inflammation or toxins, permeability rises and plasma escapes. PubMed+2Anaesthetists Publications+2

Other names

Doctors and articles may use any of these terms:

• Systemic capillary leak syndrome (SCLS)

• Clarkson disease

• Capillary leak syndrome

• Vascular leak syndrome

• Capillary hyperpermeability syndrome (your term)
  All of these describe the same core problem: sudden, severe capillary leakage of plasma. American College of Physicians Journals+1

Types

1. Primary (Idiopathic) SCLS / Clarkson disease.
   This is a rare, recurrent, and often severe form that occurs without a clear underlying disease. Many patients (about 80%) have a coexisting monoclonal gammopathy (often IgG), which is helpful for recognition but is not required for diagnosis. BioMed Central+1
2.  Secondary capillary leak.
   Here the leak happens as part of another condition, such as sepsis, severe infections (e.g., dengue or viral hemorrhagic fevers), engraftment or differentiation syndromes, ovarian hyperstimulation, HLH, autoimmune flares, snake envenomation, ricin poisoning, or as a reaction to some cancer drugs or biologics. The leak is real, but the trigger is known. PubMed+1

Causes

Below are common and well-described causes or triggers of capillary hyperpermeability. Each item explains how it can start or worsen a leak.

1. Idiopathic SCLS flare (primary).
   In primary SCLS, a trigger is not always found. A viral-like prodrome is common; the capillaries become abruptly leaky for 1–3 days and then recover. American College of Physicians Journals+1

2. Sepsis.
   Sepsis releases inflammatory mediators that damage the endothelial barrier and glycocalyx, producing profound leak and shock. SpringerOpen

3. Respiratory viral infections.
   Upper-respiratory infections often precede idiopathic SCLS attacks, likely through cytokine-driven endothelial injury. cmaj.ca

4. COVID-19 (infection or rarely vaccines).
   SCLS has been reported after COVID-19 infection and very rarely after vaccination; mechanisms are inflammatory and immune-mediated. ResearchGate

5. Dengue fever.
   Dengue can cause a marked vascular leak phase that leads to shock, especially around defervescence. journalijtdh.com

6. Viral hemorrhagic fevers (e.g., Hantavirus).
   These viruses directly injure endothelium and drive massive capillary leakage. PubMed

7. Engraftment syndrome (post-transplant).
   Cytokine surges after stem-cell transplant can produce fever, rash, and capillary leak. PubMed

8. Differentiation syndrome (e.g., with ATRA/IDH therapy).
   Rapid leukemic cell changes release cytokines that increase permeability. PubMed

9. Ovarian hyperstimulation syndrome.
   Excess vascular endothelial growth factor (VEGF) causes systemic leak, ascites, and effusions. PubMed

10. Hemophagocytic lymphohistiocytosis (HLH).
    Extreme inflammation and cytokine storm disrupt the endothelial barrier. PubMed

11. Autoimmune disease flares.
    Systemic immune activation and cytokines damage the glycocalyx and junctions. PubMed

12. Snake envenomation.
    Some venoms directly injure endothelium and provoke leak and coagulopathy. PubMed

13. Ricin and other toxins.
    Toxins can directly disrupt endothelial membranes and tight junctions. PubMed

14. Interleukin therapies (e.g., high-dose IL-2).
    Certain cytokine therapies increase vascular permeability (historically called “vascular leak syndrome”). PubMed

15. Monoclonal antibodies (various).
    Some biologics are linked to capillary leak as an idiosyncratic reaction. PubMed

16. Gemcitabine and other chemotherapies.
    Chemotherapy drugs have been associated with secondary capillary leak. PubMed

17. Severe burns.
    Thermal injury and inflammatory mediators disrupt the endothelial barrier early after injury. (General mechanism consistent with capillary leak in critical illness.) SpringerOpen

18. Anaphylaxis.
    Mast-cell mediators (histamine, leukotrienes) rapidly increase microvascular permeability. (Mechanistic basis within acute inflammatory hyperpermeability.) Anaesthetists Publications

19. Major trauma/pancreatitis.
    Systemic inflammation after trauma or pancreatic injury can drive diffuse capillary leak. (Critical illness permeability model.) SpringerOpen

20. Plasma-cell disorders (MGUS) associated with primary SCLS.
    Most adults with idiopathic SCLS have a small monoclonal protein; the protein may interact with the endothelium and mark risk. BioMed Central+1

Symptoms

Symptoms change across three phases—prodrome, leak, and recovery—and range from mild to life-threatening.

1. Flu-like prodrome.
   Many people feel feverish, achy, or have a runny nose or sore throat for 12–48 hours before an attack. PMC

2. Sudden weakness and dizziness.
   As plasma leaves the bloodstream, blood pressure drops and people feel light-headed. American College of Physicians Journals

3. Extreme thirst.
   The body senses low circulating volume and triggers thirst. American College of Physicians Journals

4. Cold, clammy skin and pallor.
   Vasoconstriction appears as the body tries to maintain blood flow to vital organs. American College of Physicians Journals

5. Swelling of arms and legs.
   Fluid collects in muscle compartments; limbs feel tight and heavy. American College of Physicians Journals

6. Rapid weight gain over hours.
   Large amounts of fluid shift into tissues during the leak phase. American College of Physicians Journals

7. Compartment pain or numbness.
   High pressure inside muscle compartments may compress nerves and vessels. Physiopedia

8. Reduced urine output.
   Kidneys receive less blood flow during shock and can fail. Physiopedia

9. Persistent clear thinking despite low blood pressure.
   A striking observation during attacks is intact mental status at presentation. Wikipedia

10. Nausea or abdominal discomfort.
    Reduced gut perfusion and tissue edema can cause discomfort. (Physiologic effect of low effective circulating volume.) American College of Physicians Journals

11. Shortness of breath in recovery.
    As fluid shifts back into vessels, lungs may fill with fluid (pulmonary edema) if fluids were over-given early. PMC

12. Cramping and muscle aches.
    Rhabdomyolysis and tissue swelling can cause pain. PMC

13. Headache or confusion later.
    If shock is prolonged, brain perfusion can fall and cause symptoms. (Critical illness physiology.) SpringerOpen

14. Fainting or near-fainting.
    Severe hypotension can lead to syncope. American College of Physicians Journals

15. Recurrent episodes over months or years.
    The pattern can be single, sporadic, or frequent relapses. JACI Online

Diagnostic tests

Diagnosis relies on history, exam, and tests done during an attack. Doctors also rule out other causes of shock (like bleeding, sepsis, and anaphylaxis).

A) Physical examination

1. Blood pressure and pulse.
   Low systolic pressure, rapid pulse, and cool extremities suggest shock from plasma loss rather than blood loss. This finding aligns with the SCLS triad. American College of Physicians Journals

2. Limb swelling and tightness.
   Tense, painful limbs suggest fluid in muscle compartments; emergency fasciotomy may be needed if pressures rise. Physiopedia

3. Mucous membranes and skin turgor.
   Dry mouth and reduced skin turgor suggest intravascular dehydration from leakage. American College of Physicians Journals

4. Lung and heart exam over time.
   Lungs may be clear during the leak phase, then develop crackles in recovery if fluids redistribute into the circulation and lungs. PMC

5. Signs of triggers.
   Look for rash, recent infection, snake bite, drug infusion, or transplant-related signs to point toward a secondary cause. PubMed

B) Bedside / manual tests

6. Orthostatic vital signs.
   Worsening dizziness and tachycardia on standing supports low intravascular volume. (Shock physiology consistent with SCLS.) American College of Physicians Journals

7. Extremity compartment pressure measurement.
   If severe limb pain and tense swelling occur, measuring compartment pressures confirms threatened compartments. Physiopedia

8. Point-of-care ultrasound (POCUS) for IVC.
   A collapsed inferior vena cava suggests low central volume; helps guide cautious fluids and vasopressors. (Critical care assessment of volume status.) SpringerOpen

9. POCUS lungs during recovery.
   Rising B-lines can warn of pulmonary edema as fluid returns to the bloodstream. (Redistribution phase of SCLS.) PMC

10. Capillary refill time.
    Prolonged refill indicates poor perfusion, supporting shock from vascular leak. (Shock bedside marker.) SpringerOpen

C) Laboratory and pathological tests

11. Complete blood count (CBC).
    Hematocrit and hemoglobin are elevated from hemoconcentration (not true polycythemia). This is part of the diagnostic triad. American College of Physicians Journals

12. Serum albumin and total protein.
    Albumin is low because it has leaked out of vessels; another element of the triad. American College of Physicians Journals

13. Electrolytes, creatinine, and BUN.
    These assess kidney injury from shock and rhabdomyolysis. PMC

14. Creatine kinase (CK) and myoglobin.
    These detect muscle injury from compartment syndrome or prolonged hypoperfusion. PMC

15. Serum/urine protein electrophoresis (SPEP/UPEP) with immunofixation.
    In idiopathic SCLS, a small monoclonal protein (often IgG) is present in ~80% of adults; finding it supports the diagnosis and follow-up. BioMed Central+1

16. Inflammatory markers (CRP, ferritin) and cytokine surrogates.
    These may be high in secondary causes (e.g., sepsis, HLH) and sometimes around idiopathic flares. PubMed

17. Infection studies (viral PCRs, blood/urine cultures, dengue tests when endemic).
    Testing helps uncover infectious triggers that cause or precipitate capillary leak. journalijtdh.com

D) Electrodiagnostic tests

18. Electrocardiogram (ECG).
    An ECG checks for ischemia or arrhythmia during shock and for effects of electrolyte changes. It also helps guide safe vasopressor use. (Standard shock work-up; capillary leak affects preload and perfusion.) SpringerOpen

E) Imaging tests

19. Chest imaging (X-ray or CT).
    During the leak phase, lungs may be relatively clear. During recovery, fluid can shift back into the circulation and cause pulmonary edema; imaging helps detect it early. PMC

20. Ultrasound or CT of abdomen and limbs.
    These may show ascites or soft-tissue edema. Imaging is also used in secondary causes like ovarian hyperstimulation or engraftment to assess severity and complications. PubMed

Non-pharmacological treatments (therapies & other measures)

1. ICU monitoring with invasive lines (arterial/central line)
   Purpose: Track blood pressure beat-to-beat and guide fluids/vasopressors.
   Mechanism: Early, tight hemodynamic control reduces under-perfusion and complications. Guidance documents emphasize careful, conservative resuscitation. FDA Access Data

2. Judicious IV fluid resuscitation
   Purpose: Restore perfusion without overfilling tissues.
   Mechanism: Small, carefully titrated boluses (often crystalloids; sometimes albumin) maintain minimal effective circulating volume while avoiding worsening edema/pulmonary edema. FDA Access Data+1

3. Early vasopressor support (e.g., norepinephrine)
   Purpose: Raise dangerously low blood pressure quickly.
   Mechanism: Stimulates vascular tone to maintain organ perfusion while fluids are cautiously given. (Label-approved for acute hypotension; disease-agnostic.) FDA Access Data

4. Albumin as a colloid adjunct (selected cases)
   Purpose: Pull fluid back into vessels and support oncotic pressure when albumin is very low.
   Mechanism: 25% human albumin increases plasma oncotic pressure; used with careful monitoring. (Labeling describes dosing principles; indication is not SCLS-specific.) Albutein+1

5. Compartment-pressure checks and emergent fasciotomy when indicated
   Purpose: Prevent limb loss and nerve/muscle death during massive swelling.
   Mechanism: Opening tight fascial compartments restores blood flow and reduces tissue pressure; numerous SCLS cases required fasciotomy. PubMed+1

6. Renal support (early dialysis/RRT if needed)
   Purpose: Manage acute kidney injury, rhabdomyolysis, and severe fluid shifts.
   Mechanism: Removes toxins/controls fluids and electrolytes during capillary leak and recovery. Case reports in SCLS describe RRT use. SpringerOpen

7. Strict input/output, daily weight, and hematocrit monitoring
   Purpose: Track leak phase and recruit phase; avoid fluid overload.
   Mechanism: Rising hematocrit and falling albumin signal active leak; later, mobilized edema demands careful diuresis timing. FDA Access Data

8. VTE (blood clot) prevention when safe
   Purpose: Reduce clot risk from hemoconcentration and immobility.
   Mechanism: Mechanical methods early; pharmacologic prophylaxis when bleeding risk is acceptable (general critical-care practice). FDA Access Data

9. Infection surveillance and early treatment
   Purpose: Viral/bacterial illnesses can trigger attacks.
   Mechanism: Prompt testing and treatment may shorten severity and prevent secondary sepsis-related capillary leak. Orpha

10. Temperature, glucose, and electrolyte control
    Purpose: Stabilize metabolism and organ function during shock.
    Mechanism: Correcting derangements supports myocardium, kidneys, and brain during low-flow states. FDA Access Data

11. Positioning and limb elevation
    Purpose: Reduce dependent edema and pain.
    Mechanism: Gravity-assisted fluid return can modestly improve swelling during leak and recovery. Physiopedia

12. Early physical therapy/rehabilitation
    Purpose: Preserve mobility and function after prolonged swelling/ICU stay.
    Mechanism: Gradual mobilization reduces deconditioning and stiffness. Physiopedia

13. Pain control (multimodal, opioid-sparing when possible)
    Purpose: Treat severe myalgia/compartment-like pain; enable breathing and mobility.
    Mechanism: Balanced analgesia while avoiding hypotension and delirium. Physiopedia

14. Careful diuresis in the recruitment phase
    Purpose: Once fluids shift back intravascularly, remove excess fluid safely.
    Mechanism: Loop diuretics after stabilization help clear edema and reduce pulmonary congestion risk. FDA Access Data

15. Vaccination planning between attacks
    Purpose: Reduce infections that may precipitate flares.
    Mechanism: Routine, guideline-based vaccination lowers viral triggers; coordinate timing with IVIG. rarediseases.org

16. Education + emergency plan
    Purpose: Recognize early signs (sudden edema, dizziness, dark urine) and seek urgent care.
    Mechanism: Faster presentation often means better outcomes. Patient orgs emphasize education. rarediseases.org

17. Nutrition support during recovery
    Purpose: Rebuild protein stores and support healing.
    Mechanism: Adequate protein/energy helps restore oncotic pressure and muscle mass. ScienceDirect

18. Avoid unnecessary large fluid loads
    Purpose: Prevent worsening third spacing and pulmonary edema.
    Mechanism: Conservative strategies are repeatedly emphasized in SCLS reviews. FDA Access Data

19. Close outpatient follow-up with SCLS-experienced team
    Purpose: Titrate IVIG prophylaxis, monitor gammopathy, and adjust meds.
    Mechanism: Regular review lowers relapse risk and catches complications early. PMC+1

20. Psychological support
    Purpose: Cope with fear of attacks and ICU stays.
    Mechanism: Counseling and peer support improve adherence and quality of life. rarediseases.org

---

Drug treatments

Acute stabilization (during an attack)

1. Norepinephrine (vasopressor)
   Class: Alpha-adrenergic agonist. Typical ICU dosing: Titrated IV to target MAP (per label). Purpose: Raise blood pressure fast. Mechanism: Vasoconstriction to support perfusion during profound hypotension. Key risks: Ischemia, arrhythmias; correct hypovolemia first. (On-label for shock; not SCLS-specific.) FDA Access Data

2. Crystalloid fluids (e.g., isotonic saline, balanced solutions)
   Class: Volume expander. Dosing: Small, repeated boluses guided by hemodynamics. Purpose: Restore minimal effective circulating volume. Mechanism: Replace intravascular volume lost to leak. Risks: Worsening edema/pulmonary edema if overdone. (Supportive standard in shock; disease-agnostic.) FDA Access Data

3. Albumin 25% (colloid adjunct)
   Class: Human albumin solution. Dosing: Individualized; used in selected hypotensive, hypoalbuminemic states. Purpose: Oncotic support with less interstitial spread than crystalloids. Mechanism: Raises plasma oncotic pressure to recruit fluid intravascularly. Risks: Fluid overload, hypersensitivity. (Labeling is general; use in SCLS is off-label.) Albutein+1

4. Phenylephrine or vasopressin (alternatives/adjuncts)
   Class: Vasopressor. Dosing: ICU titration. Purpose: Additional BP support if norepinephrine inadequate or contraindicated. Risks: Ischemia, arrhythmias. (General shock labels; off-label in SCLS.) FDA Access Data

5. Glucocorticoids (e.g., methylprednisolone—variable use)
   Class: Corticosteroid. Dosing: ICU-directed; not standardized for SCLS. Purpose: Some clinicians trial steroids in severe inflammatory leak. Mechanism: Anti-inflammatory effects; evidence in SCLS is limited/mixed. Risks: Hyperglycemia, infection. (Off-label; consider case-by-case.) Cleveland Clinic

6. Empiric antibiotics—when infection is suspected
   Class: Antibacterials. Purpose: Treat sepsis triggers that can mimic or precipitate leak. Mechanism: Pathogen-directed therapy once cultures return. Note: Not for idiopathic SCLS without infection. ScienceDirect

7. Analgesics (e.g., acetaminophen, carefully selected opioids)
   Purpose: Control severe pain from swelling/compartment pressure. Mechanism: Improves ventilation and mobilization. Risks: Hypotension/respiratory depression (opioids). Physiopedia

8. Loop diuretics (recruitment phase only)
   Class: Diuretic. Dosing: After hemodynamic stabilization. Purpose: Remove excess fluid as it shifts back intravascularly. Risks: Hypotension, electrolyte imbalance if used too early. FDA Access Data

Prevention between attacks (prophylaxis)

9. Intravenous immunoglobulin (IVIG) – cornerstone prophylaxis
   Class: Immunomodulator (human IgG). Dosing: Commonly 1–2 g/kg monthly; some use 0.4–2 g/kg/month; tailored to response. Purpose: Dramatically reduce frequency/severity of attacks. Mechanism: Proposed neutralization of pathogenic factors and stabilization of endothelium. Evidence: Case series and cohort data show substantial flare reduction and better survival. Risks: Thrombosis, renal dysfunction—hydrate and monitor per label. (Off-label for SCLS; label indications are PI/ITP/CIDP, etc.) U.S. Food and Drug Administration+4PMC+4criteria.blood.gov.au+4

10. Theophylline (historical adjunct)
    Class: Methylxanthine (phosphodiesterase inhibitor). Dosing: Titrate to serum 10–15 mcg/mL. Purpose: Reported to reduce attacks in some patients (older experience). Mechanism: Increases intracellular cAMP, may tighten endothelial junctions. Risks: Narrow therapeutic window; arrhythmias, seizures at high levels. (Off-label.) FDA Access Data+2FDA Access Data+2

11. Terbutaline (historical adjunct)
    Class: β2-agonist. Dosing: Common oral dosing 2.5–5 mg up to TID in pulmonary indications; use in SCLS is off-label. Purpose: Older reports suggest fewer flares when combined with theophylline. Mechanism: β2-agonism raises cAMP in endothelium/smooth muscle. Risks: Tremor, tachycardia; oral form not approved for tocolysis. (Off-label for SCLS.) DailyMed

12. IVIG in acute flares (select centers)
    Class: Immunoglobulin. Dosing: High-dose IVIG given early during attacks has shown improvement in some reports alongside conservative fluids. Note: Practice varies; more data emerging. American College of Physicians Journals

13. Vasopressor combinations (e.g., adding vasopressin)
    Purpose: Multi-receptor support in refractory hypotension. Mechanism: Complementary vascular effects; general shock practice. FDA Access Data

14. Prophylactic antivirals/antimicrobials – not routine
    Purpose: Not generally used; consider only for specific exposures. Rationale: No evidence they prevent idiopathic SCLS attacks. JACI Online

15. Anticoagulation (individualized)
    Purpose: Treat confirmed thrombosis or high VTE risk; timing balanced against procedures/bleeding risk. Mechanism: Prevent clot propagation in hemoconcentrated states. FDA Access Data

16. Electrolyte repletion protocols
    Purpose: Prevent arrhythmias during β-agonist use or diuresis. Mechanism: Maintain K+/Mg2+ in safe range; standard critical-care practice. FDA Access Data

17. Proton-pump inhibitor (stress ulcer prophylaxis)
    Purpose: Reduce GI bleeding risk during shock/vasopressors. Mechanism: Gastric acid suppression in ICU patients at risk. FDA Access Data

18. Insulin protocols (if steroid-induced hyperglycemia)
    Purpose: Maintain glycemic control; improve outcomes. Mechanism: Continuous or scheduled insulin in ICU. FDA Access Data

19. Antiemetics, bowel regimen, sleep aids (symptom control)
    Purpose: Improve comfort and participation in care. Mechanism: Supportive. FDA Access Data

20. Vaccines (routine, per guidelines)
    Purpose: Lower infection-triggered flares; coordinate with IVIG timing. Mechanism: Immune priming; schedule per age/conditions. rarediseases.org

⚠️ Regulatory note: For the drug labels above, FDA approvals are for the labeled indications (e.g., norepinephrine for acute hypotension; IVIG for PI/ITP/CIDP, etc.). Use in SCLS is largely off-label and based on case series, cohort analyses, and expert reviews. See the Privigen label warnings for thrombosis/renal risk and monitoring requirements. FDA Access Data+2U.S. Food and Drug Administration+2

---

Dietary molecular supplements

There are no supplements proven to prevent SCLS attacks. The ideas below come from general endothelial/critical-care nutrition science. Discuss locally before use.

1. Oral rehydration solutions (ORS) between attacks – maintain hydration; avoid extreme dehydration that may worsen hemoconcentration. FDA Access Data

2. Balanced protein intake – rebuild albumin and muscle after attacks; part of nutrition support. ScienceDirect

3. Omega-3 fatty acids – general anti-inflammatory effects; extrapolated from critical-care nutrition. ScienceDirect

4. Vitamin C (dietary levels) – supports collagen/capillary integrity in general; high-dose IV use is not established for SCLS. ScienceDirect

5. Vitamin D (correct deficiency) – immune modulation broadly; SCLS-specific data lacking. ScienceDirect

6. Zinc (correct deficiency) – wound/immune support; no SCLS-specific proof. ScienceDirect

7. Thiamine (B1) – supports energy metabolism; used broadly in critical illness; no SCLS-specific trials. ScienceDirect

8. Magnesium (correct deficiency) – helps arrhythmia prevention during β-agonist therapy/diuresis. FDA Access Data

9. Selenium (replete if low) – antioxidant roles in ICU nutrition; SCLS-specific data lacking. ScienceDirect

10. General multinutrient diet pattern (Mediterranean-style) – anti-inflammatory dietary pattern; supportive only. ScienceDirect

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved immune-booster, regenerative, or stem-cell drugs for SCLS. Outside clinical trials, these should not be used. The only preventive therapy with consistent benefit is IVIG, which is an immunomodulator, not a stem-cell product. If you see claims online about stem cells curing SCLS, they are not supported by authoritative sources. PMC+1

---

Surgeries / procedures (when and why)

1. Emergency fasciotomy for limb compartment syndrome – indicated when tissue pressures rise and perfusion is threatened; several SCLS cases required multi-limb fasciotomies to prevent limb loss. PubMed+1

2. Decompressive procedures for abdominal compartment syndrome – rare; reported in severe, diffuse edema cases. springermedizin.de

3. Dialysis catheter placement – for renal replacement therapy during severe AKI. SpringerOpen

4. Endotracheal intubation/mechanical ventilation – if respiratory failure develops (e.g., due to massive edema or shock). FDA Access Data

5. Central venous and arterial catheterization – for hemodynamic monitoring and medication delivery in ICU. FDA Access Data

---

Preventions

1. Monthly IVIG if you meet criteria and tolerate it—most effective way known to cut attacks. Hydrate and monitor for clot/renal risks. PMC+1

2. Prompt infection care – test/treat viral and bacterial illnesses quickly. Orpha

3. Routine vaccinations (per age/health) to reduce infectious triggers. rarediseases.org

4. Carry an emergency plan – list of diagnosis, usual hematocrit/albumin, treating physicians, and “SCLS attack” instructions for ED/ICU. rarediseases.org

5. Hydrate sensibly – avoid extreme dehydration; do not “self-load” large fluids during a flare without medical guidance. FDA Access Data

6. Avoid unnecessary vasodilators during prodrome (discuss with clinician). JACI Online

7. Monitor for prodromal symptoms – sudden swelling, dizziness, flu-like symptoms; seek care early. rarediseases.org

8. Regular specialist follow-up – adjust IVIG dose/intervals, review triggers, check paraprotein. criteria.blood.gov.au

9. Healthy, protein-adequate diet and activity – support recovery and albumin repletion between attacks. ScienceDirect

10. Medication review – ensure all clinicians know you have SCLS; avoid drug interactions with theophylline/terbutaline if used. FDA Access Data+1

---

When to see a doctor (or go to the ER)

• Immediately for sudden, diffuse swelling, dizziness/fainting, very dark urine, muscle pain out of proportion, cold/pale limbs, or chest/shortness of breath—these may be an SCLS flare or compartment syndrome. Early hospital care saves lives and limbs. PubMed

• Call your specialist urgently for a new infection, fever with swelling, or if you missed IVIG and feel unwell. rarediseases.org

• Routine visits every few months between attacks to review IVIG response and triggers. criteria.blood.gov.au

---

What to eat & what to avoid

• Eat: balanced meals with adequate protein (fish, eggs, legumes, dairy), fruits/vegetables, whole grains, and healthy fats (olive oil, nuts). (Supports recovery.) ScienceDirect

• Hydrate: regular water/ORS as advised, especially in heat/illness; avoid extremes. FDA Access Data

• Limit: very salty ultra-processed foods that can worsen edema. ScienceDirect

• Avoid: self-directed high-volume fluid “loading” during a prodrome/flare—this can worsen third spacing; seek medical care. FDA Access Data

• Caffeine/alcohol: moderate intake; avoid excess that dehydrates or interacts with medicines (e.g., theophylline). FDA Access Data

• Supplements: only correct deficiencies (vitamin D, magnesium, thiamine) or use simple omega-3s after discussing with your clinician; no supplement prevents SCLS. ScienceDirect

---

FAQs

1) Is SCLS the same as “capillary hyperpermeability syndrome”?
Yes—SCLS/Clarkson disease is the classic idiopathic form of sudden, reversible whole-body capillary hyperpermeability. Orpha

2) What sets off attacks?
Often a viral-like illness; sometimes unknown. Keeping vaccinations up to date and seeking early care for infections may help. Orpha+1

3) What are the hallmark labs during a flare?
Low blood pressure, high hematocrit, and low albumin, usually with hemoconcentration and edema. Orpha

4) Can IVIG really prevent attacks?
Yes, many cohorts and series show large reductions in flares and improved survival with monthly IVIG (off-label). PMC+1

5) Are theophylline and terbutaline still used?
Sometimes, historically—especially before IVIG was common—but they require careful monitoring and have more side effects. Physiopedia+1

6) Why not give lots of fluids fast?
Over-resuscitation worsens edema and can cause compartment syndrome and pulmonary edema. Conservative, guided fluids plus vasopressors are preferred. FDA Access Data

7) Can SCLS cause limb-threatening complications?
Yes; compartment syndrome may require emergency fasciotomy to save limbs. PubMed

8) Is there a cure?
No cure yet. Many patients achieve good control and fewer attacks with IVIG and careful trigger management. PMC

9) Is IVIG safe?
It’s generally well-tolerated, but risks include thrombosis and kidney injury. Hydration and monitoring per label reduce risks. U.S. Food and Drug Administration

10) Do stem cells help?
No approved or proven stem-cell therapies for SCLS. Avoid such claims outside clinical trials. JACI Online

11) Can children get SCLS?
Yes, though it’s rarer; pediatric cases exist and also respond to IVIG in reports. revistasccot.org

12) Is SCLS related to cancer?
Some adults have a monoclonal gammopathy; your team may monitor for this over time. FDA Access Data

13) What happens after an attack?
Swollen tissues “recruit” fluid back into blood; diuretics are often started then, not during the initial leak. FDA Access Data

14) Can pregnancy or surgery trigger flares?
Any major physiologic stress might; coordinate closely with specialists for planning. JACI Online

15) Who should coordinate my care?
An allergist/immunologist or internal medicine specialist familiar with SCLS, plus ICU/vascular/renal teams as needed. JACI Online

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 10, 2025.